আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 250 míkróg/10 míkróg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 50 míkróg/5 míkróg

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

aziende chimiche riunite angelini francesco s.p.a. - lurasidón - geðklofa - psycholeptics - meðferð við geðklofa hjá fullorðnum 18 ára og eldri.

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 og 5.

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - darunavir propylene glycolate - filmuhúðuð tafla - 600 mg

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation - budesonidum inn; formoterolum fúmarat - innöndunarduft - 160 míkróg/4,5 míkróg/skammt

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation - budesonidum inn; formoterolum fúmarat - innöndunarduft - 320 míkróg/9 míkróg/skammt

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

astrazeneca a/s - budesonidum inn; formoterolum fúmarat - innöndunarduft - 320/9 míkróg/skammt